Physician profile
William Howard Simons
NPI 1699726778
$1,313.17
in general payments reported to CMS, 2019-2025
9 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $11.38 · 2021: $262 · 2022: $78.92 · 2023: $178 · 2024: $171 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $629.88 | 2019-2025 | Precision 1, Dailies, Dailies Total1 |
| Allergan, INC. | $211.81 | 2019-2021 | |
| Glaukos Corporation | $133.29 | 2025 | Istent Infinite |
| Coopervision INC. | $111.72 | 2019-2025 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $77.66 | 2025 | Miebo, Xiidra, Infuse |
| Dompe US, INC. | $54.47 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $37.75 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $36.25 | 2019 | |
| Abbvie INC. | $20.34 | 2023 | Lumigan, Alphagan P, Vuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.